This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| HIV-associated neurocognitive disorder | |
|---|---|
| Name | HIV-associated neurocognitive disorder |
| Field | Infectious disease, Neurology |
| Symptoms | Cognitive impairment, motor dysfunction, behavioral changes |
| Complications | Dementia, opportunistic infections |
| Onset | Variable |
| Causes | Human immunodeficiency virus infection |
| Risks | Advanced immunosuppression, aging, substance use |
| Diagnosis | Neuropsychological testing, neuroimaging, laboratory assays |
| Treatment | Antiretroviral therapy, symptomatic management |
| Prognosis | Variable |
HIV-associated neurocognitive disorder is a spectrum of cognitive, motor, and behavioral impairments linked to infection by the human immunodeficiency virus. It occurs in people with HIV and spans asymptomatic neurocognitive impairment to severe HIV-associated dementia, affecting executive function, memory, attention, and motor speed. Recognition and management intersect with neurology, infectious disease, geriatrics, and psychiatry services.
Presentations range from subtle deficits to profound dementia. Patients may exhibit impaired attention, slowed processing speed, memory deficits, executive dysfunction, apathy, mood lability, and motor disturbances such as gait abnormalities and fine motor slowing. Activities of daily living may be affected, with vocational decline and increased risk of accidents. Behavioral and psychiatric features include depression, irritability, and social withdrawal, which can complicate adherence to antiretroviral regimens.
Pathogenesis involves HIV entry into the central nervous system via infected monocytes and lymphocytes crossing the blood–brain barrier. Viral proteins and host immune activation produce neuroinflammation, microglial activation, astrocyte dysfunction, excitotoxicity, and synaptodendritic injury. Co-pathologies such as cerebrovascular disease, amyloid deposition, and co-infection with tuberculosis or hepatitis C can modify expression. Genetic host factors and age-related neurodegeneration interact with persistent viral reservoirs and antiretroviral neurotoxicity to shape disease.
Diagnosis requires correlation of cognitive testing, neuroimaging, laboratory assays, and clinical history. Neuropsychological batteries assess domains including attention, learning, memory, language, executive function, and motor skills, with impairment measured against normative data. Brain MRI may show diffuse or focal white matter changes or atrophy; PET and MR spectroscopy can reveal metabolic abnormalities. Cerebrospinal fluid analysis detects HIV RNA, inflammatory markers, and excludes opportunistic infections such as cryptococcal meningitis. Differential diagnosis considers major neurocognitive disorders due to Alzheimer disease, vascular dementia, substance-related disorders, and psychiatric conditions.
Clinical categories stratify severity and functional impact. Asymptomatic neurocognitive impairment denotes objective testing deficits without functional decline; mild neurocognitive disorder includes both cognitive impairment and mild functional impairment; HIV-associated dementia reflects marked cognitive decline with substantial impairment in daily functioning. Staging systems integrate neuropsychological performance, functional status, and level of immune suppression to guide prognosis and management.
Primary prevention centers on HIV prevention strategies and early antiretroviral therapy initiation to limit CNS seeding. Combination antiretroviral therapy reduces incidence and severity but does not eliminate risk; regimen selection may consider CNS penetration effectiveness. Management includes optimizing virologic suppression, addressing comorbidities such as cardiovascular disease and substance use, and rehabilitative interventions including cognitive remediation and occupational therapy. Symptomatic pharmacologic treatments for mood, psychosis, or motor symptoms may be used. Clinical trials investigate neuroprotective agents, anti-inflammatory therapies, and strategies to target CNS reservoirs.
Prevalence and incidence vary with access to diagnosis and antiretroviral therapy. In high-income settings with widespread therapy, severe dementia has declined, while milder forms persist among aging populations. Global patterns reflect HIV epidemic distribution, with higher burden in regions with limited treatment access. Demographic and social factors including age, injection drug use, and late presentation to care influence risk.
Outcomes depend on severity at presentation, degree of virologic control, comorbid conditions, and adherence to therapy. Some individuals experience cognitive stability or improvement with effective antiretroviral therapy; others progress despite treatment due to persistent inflammation, co-pathology, or neurodegeneration. Long-term disability can affect employment, independence, and quality of life, necessitating multidisciplinary care and social support.